Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

On Demand Series

Recent Developments in Gene Targeted and Immunotherapies of Parkinson Disease

Length:60 MinutesCME Credits:1Release Date:Jun 26, 2020

Experienced / IntermediateExpert / AdvancedOn Demand Series

Program Description

The Recent Developments in Gene Targeted and Immunotherapies of Parkinson Disease webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.

The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.

The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD. Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.


  • Basic/Translational Neuroscience
  • Biomarkers & Diagnostic Tools
  • Therapies-Pharmacological


Carlos Singer, MD ; Roy N. Alcalay, MD ; Joseph Quinn, MD

Course Purpose

The primary purpose of this program is to provide information on gene therapy.

Learning Objectives

Upon completion of this activity learners will be able to:
1. Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
2. Explain the current state of development of clinical trials of both therapies
3. Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
4. Identify future directions of these novel therapeutic modalities

Intended Audience

This activity is intended for neurologists interested or specializing in Movement Disorders.

Accreditation Credit

The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Method of Participation

The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Faculty Disclosure


Staff Disclosure

MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Hardware and Software Requirements

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.

Contact Us

Allie Oakley


All individuals in control of content for this course are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME.

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice